For instance, a 10-day decitabine regimen in patients with AML led to an excellent 100% ORR in patients with mutated TP53 disease compared to 41% in those with wt TP53 (p < 0.001), however was not sufficient for mutational clearance. Here, TP53 is linked to acute myeloid leukemia.